• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Nuclear Medicine Market Analysis

    ID: MRFR/HC/5211-CR
    200 Pages
    Rahul Gotadki
    July 2025

    Nuclear Medicine Market Research Report By Application (Diagnostic Imaging, Therapeutic Applications, Radiopharmaceutical Production, Research Applications), By Radioisotope Type (Technetium-99m, Iodine-131, Fluorine-18, Yttrium-90), By End User (Hospitals, Diagnostic Imaging Centers, Academic Research Institutions, Pharmaceutical Companies), By Procedure (Positron Emission Tomography, Single-P...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Nuclear Medicine Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Analysis

    In-depth Analysis of Nuclear Medicine Market Industry Landscape

    The changing landscape of diagnostic options available today is largely influenced by the interplay between advanced medical imaging technology & therapeutic applications called nuclear medicine market dynamics. A major factor driving the Nuclear Medicine market is the growing demand for more accurate personalized diagnostics tests. PET & SPECT techniques offer insight into molecular processes & physiological functions, enabling the detection of early disease stages & planning individualized treatments. Advancements in medical research and technology shape the ever-changing dynamics within the Nuclear Medicine market. Pharmaceutical companies and imaging technology manufacturers also pour their investments into developing radiopharmaceuticals as well as imaging devices aimed at improving diagnostic accuracy and therapeutic efficacy. The changing nature of the market, however, is made possible through the introduction of novel radiotracers, hybrid imaging systems, and targeted therapeutics. Regulatory factors play a major role in defining the dynamics of this market. Stringent regulations govern the approval, production, and use of medical isotopes & radiopharmaceuticals, as well as imaging devices, which must comply with safety, efficacy, and radiation protection standards. For pharmaceutical firms developing these drugs or investigating these diseases, for instance, they must follow set regulatory guidelines; whether such will hinder or allow them to gain entry into a country's market is considered before any strategy is commenced. Economic considerations greatly influence the accessibility of nuclear medicine procedures. Cost-effective early diagnostics remain critical given the economic burden associated with chronic diseases such as cancer and cardiovascular pathologies. Nevertheless, the availability and utilization of nuclear medicine imaging modalities will ultimately depend on affordability, insurance coverage policies, and reimbursement mechanisms that may differ from one health system to another within a country. Among the dynamics that characterize the Nuclear Medicine industry, one can mention the competitive landscape among pharmaceutical companies, imaging technology manufacturers, and healthcare institutions. The development and marketing of state-of-the-art radiopharmaceuticals, imaging devices, and therapeutic applications are what firms vie for. Strategic alliances, partnerships, and research activities drive innovations in this industry. Also impacting the Nuclear Medicine market are global demographic trends such as aging populations and an increasing incidence of chronic diseases. Growing diagnostic needs from an aging population with complex medical conditions require more advanced imaging techniques. At the same time, a greater prevalence of chronic diseases necessitates better therapeutics using nuclear medicine, which remains relevant to prevailing health issues in modern times. Stakeholders within the Nuclear Medicine market must understand this shift in demographics so as to develop strategies that align with the evolving healthcare system.

    Market Summary

    As per MRFR analysis, the Nuclear Medicine Market Size was estimated at 10.63 USD Billion in 2024. The Nuclear Medicine industry is projected to grow from 11.84 USD Billion in 2025 to 34.69 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 11.35 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Nuclear Medicine Market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

    • North America remains the largest market for nuclear medicine, driven by advanced healthcare infrastructure and high adoption rates.
    • The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing investments in healthcare and rising patient populations.
    • Diagnostic imaging continues to dominate the market, while therapeutic applications are experiencing rapid growth due to advancements in treatment methodologies.
    • Key market drivers include the increasing incidence of cancer and rising awareness of nuclear medicine, which are propelling demand across various segments.

    Market Size & Forecast

    2024 Market Size 10.63 (USD Billion)
    2035 Market Size 34.69 (USD Billion)
    CAGR (2025 - 2035) 11.35%
    Largest Regional Market Share in 2024 North America

    Major Players

    <p>GE Healthcare (US), Siemens Healthineers (DE), Philips Healthcare (NL), Canon Medical Systems (JP), Elekta (SE), Bayer AG (DE), Bracco Imaging (IT), Lantheus Medical Imaging (US), NorthStar Medical Radioisotopes (US)</p>

    Market Trends

    The Nuclear Medicine Market is currently experiencing a transformative phase, characterized by advancements in technology and an increasing emphasis on personalized medicine. The integration of innovative imaging techniques and radiopharmaceuticals is enhancing diagnostic accuracy and treatment efficacy. As healthcare systems worldwide strive to improve patient outcomes, the demand for nuclear medicine is likely to rise. Furthermore, the growing prevalence of chronic diseases necessitates the development of targeted therapies, which nuclear medicine can provide. This sector appears poised for growth, driven by ongoing research and development efforts aimed at expanding the applications of nuclear medicine in various therapeutic areas. In addition, the Nuclear Medicine Market is witnessing a shift towards more sustainable practices, with a focus on minimizing waste and optimizing resource utilization. Regulatory bodies are increasingly advocating for environmentally friendly approaches in the production and disposal of radiopharmaceuticals. This trend may lead to the emergence of new technologies that prioritize safety and sustainability, potentially reshaping the landscape of nuclear medicine. As the market evolves, stakeholders must remain vigilant to adapt to these changes and leverage opportunities that arise from the dynamic environment.

    Technological Advancements

    The Nuclear Medicine Market is benefiting from rapid technological innovations, particularly in imaging modalities and radiopharmaceutical development. Enhanced imaging techniques are improving diagnostic capabilities, while novel radiopharmaceuticals are being designed for targeted therapies, potentially increasing treatment effectiveness.

    Personalized Medicine

    There is a growing trend towards personalized medicine within the Nuclear Medicine Market. Tailoring treatments to individual patient profiles is becoming more prevalent, as it may lead to improved outcomes and reduced side effects, thereby enhancing the overall patient experience.

    Sustainability Initiatives

    The Nuclear Medicine Market is increasingly focusing on sustainability, with efforts to reduce environmental impact. This includes the development of eco-friendly radiopharmaceuticals and waste management practices, which could lead to a more responsible approach in the industry.

    <p>The Global Nuclear Medicine Market is poised for growth, driven by advancements in radiopharmaceuticals and increasing applications in diagnostics and therapeutics, which collectively enhance patient care and treatment outcomes.</p>

    U.S. Department of Energy

    Nuclear Medicine Market Market Drivers

    Aging Population

    The aging population is a significant factor influencing the Nuclear Medicine Market. As individuals age, the prevalence of chronic diseases, including cardiovascular disorders and cancer, tends to increase. This demographic shift is driving the need for advanced diagnostic and therapeutic options that nuclear medicine provides. Older adults often require more frequent medical evaluations, and nuclear medicine techniques are particularly effective in assessing complex health conditions. The World Health Organization has indicated that the proportion of older individuals is expected to rise, leading to a greater demand for healthcare services. Consequently, the nuclear medicine sector is likely to expand as it caters to the needs of this growing demographic, offering tailored solutions for age-related health issues.

    Increasing Incidence of Cancer

    The rising incidence of cancer worldwide is a primary driver for the Nuclear Medicine Market. As cancer rates continue to escalate, the demand for effective diagnostic and therapeutic solutions becomes more pronounced. Nuclear medicine offers advanced imaging techniques, such as positron emission tomography (PET), which are crucial for early detection and treatment planning. According to recent statistics, cancer cases are projected to increase significantly, necessitating innovative approaches in patient management. This trend underscores the importance of nuclear medicine in oncology, as it provides targeted therapies that can improve patient outcomes. The growing recognition of the role of nuclear medicine in cancer care is likely to propel market growth, as healthcare providers seek to incorporate these technologies into their treatment protocols.

    Rising Awareness of Nuclear Medicine

    There is a growing awareness of the benefits of nuclear medicine among healthcare professionals and patients, which is positively impacting the Nuclear Medicine Market. Educational initiatives and outreach programs are helping to disseminate information about the advantages of nuclear imaging and therapy. As more healthcare providers recognize the efficacy of nuclear medicine in diagnosing and treating various conditions, the adoption of these technologies is expected to increase. Additionally, patient awareness campaigns are encouraging individuals to seek nuclear medicine services for better health outcomes. This heightened awareness is likely to drive market growth, as both providers and patients become more informed about the potential of nuclear medicine in enhancing diagnostic accuracy and treatment efficacy.

    Technological Innovations in Imaging

    Technological advancements in imaging modalities are transforming the Nuclear Medicine Market. Innovations such as hybrid imaging systems, which combine PET and computed tomography (CT), enhance diagnostic accuracy and patient management. These systems allow for precise localization of tumors and assessment of treatment response, thereby improving clinical decision-making. The market for nuclear imaging is expected to witness substantial growth, driven by the introduction of novel radiopharmaceuticals and imaging agents. Furthermore, advancements in detector technology and software algorithms are enhancing image quality and reducing radiation exposure. As healthcare facilities increasingly adopt these cutting-edge technologies, the demand for nuclear medicine services is anticipated to rise, reflecting a shift towards more sophisticated diagnostic capabilities.

    Investment in Research and Development

    Investment in research and development (R&D) is a crucial driver for the Nuclear Medicine Market. Increased funding for the development of new radiopharmaceuticals and imaging technologies is fostering innovation within the sector. Governments and private organizations are recognizing the importance of nuclear medicine in addressing unmet medical needs, leading to enhanced R&D initiatives. This focus on innovation is expected to yield novel diagnostic and therapeutic agents that can improve patient care. Furthermore, collaborations between academic institutions and industry players are likely to accelerate the pace of discovery and commercialization of new products. As R&D continues to advance, the nuclear medicine market is poised for growth, with the potential to introduce groundbreaking solutions that address current healthcare challenges.

    Market Segment Insights

    By Application: Diagnostic Imaging (Largest) vs. Therapeutic Applications (Fastest-Growing)

    <p>The nuclear medicine market is prominently driven by the Diagnostic Imaging segment, which holds the largest share among application areas. This segment encompasses a range of imaging techniques, including PET and SPECT, which facilitate the visualization of physiological processes in the body. Conversely, Therapeutic Applications are gaining momentum due to advancements in targeted therapies, positioning them as the fastest-growing area within the market. This shift is reflective of a broader trend towards personalized treatment paradigms in healthcare.</p>

    <p>Diagnostic Imaging (Dominant) vs. Therapeutic Applications (Emerging)</p>

    <p>Diagnostic Imaging remains the dominant application in nuclear medicine, characterized by its extensive use in detecting diseases and monitoring treatment efficacy. This segment leverages advanced imaging technologies such as PET scans, which provide precise anatomical and functional insights, making it invaluable in oncology and cardiology. On the other hand, Therapeutic Applications are emerging rapidly, driven by innovations in radiotherapy techniques and the development of new radiopharmaceuticals for treatment purposes. These therapies offer targeted action on disease sites, thereby minimizing collateral damage to healthy tissue. The momentum behind both segments demonstrates the evolving landscape of nuclear medicine, catering to a growing demand for effective diagnosis and treatment.</p>

    By Radioisotope Type: Technetium-99m (Largest) vs. Fluroine-18 (Fastest-Growing)

    <p>Within the Nuclear Medicine Market, the distribution of market share among radioisotope types reveals Technetium-99m as the dominant player. Accounting for a significant portion of diagnostic imaging procedures, it is preferred due to its ideal physical properties, leading to widespread adoption across healthcare facilities. Following Technetium-99m, Iodine-131 also holds a substantial share, primarily used in therapeutic applications, while Fluorine-18 is emerging rapidly, driven by the increasing prevalence of PET scans in oncology. Yttrium-90, although smaller in share, finds niche applications in targeted therapies for liver cancer.</p>

    <p>Technetium-99m (Dominant) vs. Fluorine-18 (Emerging)</p>

    <p>Technetium-99m has long been established as the most widely used radioisotope in Nuclear Medicine, primarily due to its optimal half-life, allowing for effective imaging with minimal patient exposure to radiation. Its versatility in various diagnostic procedures, particularly in single-photon emission computed tomography (SPECT), has solidified its position as a dominant force. Conversely, Fluorine-18 is emerging as a key player, particularly in positron emission tomography (PET) imaging. The surge in demand for accurate cancer diagnosis and monitoring has propelled its growth, making it one of the fastest-growing isotopes in the market. As technological advancements and healthcare investments continue, both Technetium-99m and Fluorine-18 will play critical roles in shaping the future landscape of nuclear medicine.</p>

    By End User: Hospitals (Largest) vs. Diagnostic Imaging Centers (Fastest-Growing)

    <p>The nuclear medicine market is primarily influenced by its end user segments, which include hospitals, diagnostic imaging centers, academic research institutions, and pharmaceutical companies. Among these, hospitals hold the largest share, driven by their integrated healthcare services offering a wide range of diagnostic and therapeutic applications. In contrast, diagnostic imaging centers are rapidly escalating in market share due to the increase in demand for specialized imaging techniques and procedures that utilize nuclear medicine, contributing significantly to the market growth.</p>

    <p>Hospitals (Dominant) vs. Diagnostic Imaging Centers (Emerging)</p>

    <p>In the nuclear medicine market, hospitals serve as the dominant end user segment, providing comprehensive patient care through a variety of nuclear medicine procedures such as diagnostic imaging and targeted therapies. Their established infrastructure enables the integration of advanced nuclear technologies, enhancing patient turnaround and treatment efficiency. Conversely, diagnostic imaging centers are emerging as a robust segment, capitalizing on the growing demand for non-invasive diagnostic techniques and advancements in imaging technologies. Their ability to focus specifically on imaging services allows for specialization, leading to a rapid increase in adoption rates and market penetration.</p>

    By Procedure: Positron Emission Tomography (Largest) vs. Single-Photon Emission Computed Tomography (Fastest-Growing)

    <p>In the Nuclear Medicine Market, Positron Emission Tomography (PET) currently holds a significant share, demonstrating its vital role in diagnostic imaging. It is widely recognized for its ability to detect metabolic changes at the cellular level, making it a preferred choice among healthcare providers. Single-Photon Emission Computed Tomography (SPECT) also contributes substantially to the market, benefiting from its cost-effectiveness and broader application in various diagnostic procedures. The growth trends within this segment are primarily driven by technological advancements and an increasing prevalence of chronic diseases. PET is increasingly adopted for precision medicine, while SPECT’s versatility is making it more popular across various healthcare settings. As healthcare infrastructure expands and more advanced imaging systems integrate into clinical practice, both PET and SPECT are expected to experience significant growth in the coming years.</p>

    <p>Radiotherapy (Dominant) vs. Brachytherapy (Emerging)</p>

    <p>Radiotherapy remains a dominant force in the Nuclear Medicine Market, primarily due to its extensive application in treating various types of cancers. It utilizes high doses of radiation to eliminate malignant cells, making it an essential treatment modality in oncology. The technique is widely favored for its effectiveness and continuous improvements in precision and patient safety. In contrast, Brachytherapy is an emerging segment that involves placing radioactive sources directly inside or near the tumor. Its growing popularity can be attributed to its localized treatment capabilities and reduced exposure to surrounding healthy tissues. As techniques evolve and clinical indications expand, Brachytherapy is expected to carve out a substantial presence in the market.</p>

    Get more detailed insights about Nuclear Medicine Market Research Report- Forecast till 2035

    Regional Insights

    North America : Market Leader in Innovation

    North America is the largest market for nuclear medicine, holding approximately 45% of the global share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of chronic diseases, and rising investments in research and development. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring safety and efficacy in nuclear medicine applications. The United States is the primary contributor, with significant presence from key players such as GE Healthcare and Lantheus Medical Imaging. Canada also plays a vital role, focusing on innovative solutions and collaborations. The competitive landscape is characterized by continuous technological advancements and strategic partnerships among leading companies, enhancing service delivery and patient outcomes.

    Europe : Emerging Regulatory Frameworks

    Europe is the second-largest market for nuclear medicine, accounting for approximately 30% of the global share. The region benefits from stringent regulatory frameworks that promote safety and efficacy in medical applications. Increasing investments in healthcare infrastructure and a growing aging population are key drivers of market growth. Countries like Germany and the UK are at the forefront, with supportive policies enhancing the adoption of nuclear medicine technologies. Germany leads the market, supported by major players like Siemens Healthineers and Bayer AG. The competitive landscape is marked by innovation, with companies focusing on developing advanced imaging technologies and radiopharmaceuticals. Collaborative efforts among European nations to standardize regulations further strengthen the market, ensuring a robust environment for growth and development.

    Asia-Pacific : Rapidly Growing Market Potential

    Asia-Pacific is witnessing rapid growth in the nuclear medicine market, holding approximately 20% of the global share. The region's expansion is fueled by increasing healthcare expenditure, rising awareness of nuclear medicine applications, and a growing patient population. Countries like Japan and China are leading the charge, with supportive government initiatives aimed at enhancing healthcare services and technology adoption. Japan is a significant player, with companies like Canon Medical Systems driving innovation in imaging technologies. The competitive landscape is evolving, with local and international firms collaborating to enhance service delivery. The presence of key players and a focus on research and development are pivotal in establishing Asia-Pacific as a formidable market in the nuclear medicine sector.

    Middle East and Africa : Untapped Market Opportunities

    The Middle East and Africa region is gradually emerging in the nuclear medicine market, currently holding about 5% of the global share. The growth is driven by increasing investments in healthcare infrastructure, rising awareness of nuclear medicine, and government initiatives aimed at improving healthcare access. Countries like South Africa and the UAE are making strides in adopting advanced medical technologies, which is expected to boost market growth. South Africa is a key player, with a focus on enhancing diagnostic capabilities through nuclear medicine. The competitive landscape is characterized by a mix of local and international companies striving to establish a foothold in this developing market. As healthcare systems evolve, the potential for growth in nuclear medicine is significant, presenting opportunities for innovation and investment.

    Key Players and Competitive Insights

    The Nuclear Medicine Market is currently characterized by a dynamic competitive landscape, driven by advancements in technology, increasing demand for diagnostic imaging, and a growing emphasis on personalized medicine. Major players such as GE Healthcare (US), Siemens Healthineers (DE), and Bayer AG (DE) are strategically positioned to leverage these trends. GE Healthcare (US) focuses on innovation in imaging technologies, particularly in hybrid imaging systems that combine nuclear medicine with other modalities. Siemens Healthineers (DE) emphasizes digital transformation and AI integration to enhance diagnostic accuracy and operational efficiency. Bayer AG (DE) is actively pursuing partnerships to expand its radiopharmaceutical portfolio, thereby enhancing its market presence. Collectively, these strategies indicate a shift towards more integrated and technologically advanced solutions in the nuclear medicine sector.

    Key business tactics within the Nuclear Medicine Market include localizing manufacturing and optimizing supply chains to enhance responsiveness to regional demands. The market appears moderately fragmented, with a mix of established players and emerging companies. The collective influence of key players is significant, as they not only drive innovation but also set industry standards that smaller firms often follow. This competitive structure fosters an environment where collaboration and strategic partnerships are essential for growth and sustainability.

    In August 2025, Siemens Healthineers (DE) announced a collaboration with a leading AI firm to develop advanced imaging algorithms aimed at improving the accuracy of PET scans. This strategic move is likely to enhance Siemens' product offerings and solidify its position as a leader in the integration of AI within nuclear medicine, potentially leading to better patient outcomes and increased market share.

    In September 2025, Bayer AG (DE) launched a new radiopharmaceutical designed for targeted therapy in oncology. This introduction not only expands Bayer's therapeutic options but also reflects a growing trend towards personalized medicine in nuclear treatments. The strategic importance of this launch lies in its potential to address unmet medical needs, thereby enhancing Bayer's competitive edge in the oncology segment of the market.

    In July 2025, GE Healthcare (US) unveiled a new line of compact PET/CT scanners aimed at smaller healthcare facilities. This initiative appears to be a response to the increasing demand for accessible imaging solutions in underserved regions. By localizing production and focusing on smaller healthcare providers, GE Healthcare is likely to capture a broader market segment, reinforcing its commitment to improving healthcare accessibility.

    As of October 2025, the Nuclear Medicine Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence. These trends are reshaping competitive dynamics, with strategic alliances becoming increasingly vital for innovation and market penetration. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that companies that prioritize innovation and collaboration will likely emerge as leaders in this evolving landscape.

    Key Companies in the Nuclear Medicine Market market include

    Industry Developments

    The Nuclear Medicine Market has seen notable developments recently, particularly with advancements in technology and increasing applications in clinical settings. Major players such as GE Healthcare and Siemens Healthineers are focusing on enhancing imaging techniques, which is vital for precise diagnostics. 

    In terms of recent mergers and acquisitions, Bracco Imaging announced the acquisition of a leading radiopharmaceutical company in August 2023, augmenting their product portfolio significantly. Additionally, Bayer AG completed the purchase of a niche radiopharmaceutical business in July 2023, further consolidating their presence in the market.

    The impact of these activities is reflected in the market valuation, which is projected to grow due to technological advancements and increasing demand for targeted cancer therapies. Companies like Lantheus Medical Imaging are also expanding their offerings, which is expected to contribute to market growth in the upcoming years. 

    Other noteworthy developments in the last couple of years include the increased adoption of PET scans and the rise of personalized medicine, with advancements around March 2022 showcasing these trends gaining momentum globally. The Nuclear Medicine Market is poised for ongoing evolution as stakeholders invest in Research and Development to meet rising healthcare demands.

    Future Outlook

    Nuclear Medicine Market Future Outlook

    <p>The Nuclear Medicine Market is projected to grow at an 11.35% CAGR from 2024 to 2035, driven by technological advancements, increasing cancer prevalence, and enhanced diagnostic capabilities.</p>

    New opportunities lie in:

    • <p>Development of targeted radiopharmaceuticals for personalized medicine</p>
    • <p>Expansion of telemedicine platforms for remote patient monitoring</p>
    • <p>Investment in advanced imaging technologies for improved diagnostics</p>

    <p>By 2035, the Nuclear Medicine Market is expected to achieve substantial growth and innovation.</p>

    Market Segmentation

    Nuclear Medicine Market End User Outlook

    • Hospitals
    • Diagnostic Imaging Centers
    • Academic Research Institutions
    • Pharmaceutical Companies

    Nuclear Medicine Market Procedure Outlook

    • Positron Emission Tomography
    • Single-Photon Emission Computed Tomography
    • Radiotherapy
    • Brachytherapy

    Nuclear Medicine Market Application Outlook

    • Diagnostic Imaging
    • Therapeutic Applications
    • Radiopharmaceutical Production
    • Research Applications

    Nuclear Medicine Market Radioisotope Type Outlook

    • Technetium-99m
    • Iodine-131
    • Fluorine-18
    • Yttrium-90

    Report Scope

    MARKET SIZE 202410.63(USD Billion)
    MARKET SIZE 202511.84(USD Billion)
    MARKET SIZE 203534.69(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)11.35% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in radiopharmaceuticals enhance diagnostic accuracy in the Nuclear Medicine Market.
    Key Market DynamicsTechnological advancements and regulatory changes drive innovation and competition in the Nuclear Medicine Market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What is the current valuation of the Nuclear Medicine Market as of 2024?

    The Nuclear Medicine Market was valued at 10.63 USD Billion in 2024.

    What is the projected market valuation for the Nuclear Medicine Market in 2035?

    The market is projected to reach a valuation of 34.69 USD Billion by 2035.

    What is the expected CAGR for the Nuclear Medicine Market during the forecast period 2025 - 2035?

    The expected CAGR for the Nuclear Medicine Market during the forecast period 2025 - 2035 is 11.35%.

    Which companies are considered key players in the Nuclear Medicine Market?

    Key players in the market include GE Healthcare, Siemens Healthineers, Philips Healthcare, and Canon Medical Systems.

    What are the main application segments of the Nuclear Medicine Market?

    The main application segments include Diagnostic Imaging, Therapeutic Applications, Radiopharmaceutical Production, and Research Applications.

    How does the Diagnostic Imaging segment perform in terms of market valuation?

    The Diagnostic Imaging segment was valued at 3.5 USD Billion in 2024 and is projected to reach 12.0 USD Billion by 2035.

    What is the market valuation for the Therapeutic Applications segment?

    The Therapeutic Applications segment was valued at 2.5 USD Billion in 2024 and is expected to grow to 8.5 USD Billion by 2035.

    Which radioisotope types are significant in the Nuclear Medicine Market?

    Significant radioisotope types include Technetium-99m, Iodine-131, Fluorine-18, and Yttrium-90.

    What is the projected growth for the Pharmaceutical Companies segment in the Nuclear Medicine Market?

    The Pharmaceutical Companies segment was valued at 4.25 USD Billion in 2024 and is anticipated to reach 13.04 USD Billion by 2035.

    What procedures are included in the Nuclear Medicine Market analysis?

    The procedures analyzed include Positron Emission Tomography, Single-Photon Emission Computed Tomography, Radiotherapy, and Brachytherapy.

    1. \r\nNuclear Medicine Market, BY Application (USD Billion)
      1. \r\n\r\nDiagnostic Imaging
      2. \r\n\r\nTherapeutic Applications
      3. \r\n\r\nRadiopharmaceutical Production
      4. \r\n\r\nResearch Applications
    2. \r\n\r\nNuclear Medicine Market, BY Radioisotope Type (USD Billion)
      1. \r\n\r\nTechnetium-99m
      2. \r\n\r\nIodine-131
      3. \r\n\r\nFluorine-18
      4. \r\n\r\nYttrium-90
    3. \r\n\r\nNuclear Medicine Market, BY End User (USD Billion)
      1. \r\n\r\nHospitals
      2. \r\n\r\nDiagnostic Imaging Centers
      3. \r\n\r\nAcademic Research Institutions
      4. \r\n\r\nPharmaceutical Companies
    4. \r\n\r\nNuclear Medicine Market, BY Procedure (USD Billion)
      1. \r\n\r\nPositron Emission Tomography
      2. \r\n\r\nSingle-Photon Emission Computed Tomography
      3. \r\n\r\nRadiotherapy
      4. \r\n\r\nBrachytherapy
    5. \r\n\r\nNuclear Medicine Market, BY Regional (USD Billion)
      1. \r\n\r\nNorth America
      2. \r\n\r\nUS
      3. \r\n\r\nCanada
      4. \r\n\r\nEurope
      5. \r\n\r\nGermany
      6. \r\n\r\nUK
      7. \r\n\r\nFrance
      8. \r\n\r\nRussia
      9. \r\n\r\nItaly
      10. \r\n\r\nSpain
      11. \r\n\r\nRest of Europe
      12. \r\n\r\nAPAC
      13. \r\n\r\nChina
      14. \r\n\r\nIndia
      15. \r\n\r\nJapan
      16. \r\n\r\nSouth Korea
      17. \r\n\r\nMalaysia
      18. \r\n\r\nThailand
      19. \r\n\r\nIndonesia
      20. \r\n\r\nRest of APAC
      21. \r\n\r\nSouth America
      22. \r\n\r\nBrazil
      23. \r\n\r\nMexico
      24. \r\n\r\nArgentina
      25. \r\n\r\nRest of South America
      26. \r\n\r\nMEA
      27. \r\n\r\nGCC Countries
      28. \r\n\r\nSouth Africa
      29. \r\n\r\nRest of MEA
      30. \r\n\r\n
      31. \r\n
      32. \r\n
      33. \r\nCompetitive Landscape
      34. \r\n\r\nOverview
      35. \r\n\r\nCompetitive Analysis
      36. \r\n\r\nMarket share Analysis
      37. \r\n\r\nMajor Growth Strategy in the Nuclear Medicine Market
      38. \r\n\r\nCompetitive Benchmarking
      39. \r\n\r\nLeading Players in Terms of Number of Developments in the Nuclear Medicine Market
      40. \r\n\r\nKey developments and growth strategies
      41. \r\n\r\nNew Product Launch/Service Deployment
      42. \r\n\r\nMerger & Acquisitions
      43. \r\n\r\nJoint Ventures
      44. \r\n\r\nMajor Players Financial Matrix
      45. \r\n\r\nSales and Operating Income
      46. \r\n\r\nMajor Players R&D Expenditure. 2023
      47. \r\n\r\nCompany Profiles
      48. \r\n\r\nMediRadiant
      49. \r\n\r\nFinancial Overview
      50. \r\n\r\nProducts Offered
      51. \r\n\r\nKey Developments
      52. \r\n\r\nSWOT Analysis
      53. \r\n\r\nKey Strategies
      54. \r\n\r\nBracco Imaging
      55. \r\n\r\nFinancial Overview
      56. \r\n\r\nProducts Offered
      57. \r\n\r\nKey Developments
      58. \r\n\r\nSWOT Analysis
      59. \r\n\r\nKey Strategies
      60. \r\n\r\nNordion
      61. \r\n\r\nFinancial Overview
      62. \r\n\r\nProducts Offered
      63. \r\n\r\nKey Developments
      64. \r\n\r\nSWOT Analysis
      65. \r\n\r\nKey Strategies
      66. \r\n\r\nTheraBiologics
      67. \r\n\r\nFinancial Overview
      68. \r\n\r\nProducts Offered
      69. \r\n\r\nKey Developments
      70. \r\n\r\nSWOT Analysis
      71. \r\n\r\nKey Strategies
      72. \r\n\r\nUnited Imaging Healthcare
      73. \r\n\r\nFinancial Overview
      74. \r\n\r\nProducts Offered
      75. \r\n\r\nKey Developments
      76. \r\n\r\nSWOT Analysis
      77. \r\n\r\nKey Strategies
      78. \r\n\r\nPhilips
      79. \r\n\r\nFinancial Overview
      80. \r\n\r\nProducts Offered
      81. \r\n\r\nKey Developments
      82. \r\n\r\nSWOT Analysis
      83. \r\n\r\nKey Strategies
      84. \r\n\r\nCanon Medical Systems
      85. \r\n\r\nFinancial Overview
      86. \r\n\r\nProducts Offered
      87. \r\n\r\nKey Developments
      88. \r\n\r\nSWOT Analysis
      89. \r\n\r\nKey Strategies
      90. \r\n\r\nSelenoMed
      91. \r\n\r\nFinancial Overview
      92. \r\n\r\nProducts Offered
      93. \r\n\r\nKey Developments
      94. \r\n\r\nSWOT Analysis
      95. \r\n\r\nKey Strategies
      96. \r\n\r\nRadiopharm Theranostics
      97. \r\n\r\nFinancial Overview
      98. \r\n\r\nProducts Offered
      99. \r\n\r\nKey Developments
      100. \r\n\r\nSWOT Analysis
      101. \r\n\r\nKey Strategies
      102. \r\n\r\nAquaBounty Technologies
      103. \r\n\r\nFinancial Overview
      104. \r\n\r\nProducts Offered
      105. \r\n\r\nKey Developments
      106. \r\n\r\nSWOT Analysis
      107. \r\n\r\nKey Strategies
      108. \r\n\r\nLantheus Medical Imaging
      109. \r\n\r\nFinancial Overview
      110. \r\n\r\nProducts Offered
      111. \r\n\r\nKey Developments
      112. \r\n\r\nSWOT Analysis
      113. \r\n\r\nKey Strategies
      114. \r\n\r\nBayer
      115. \r\n\r\nFinancial Overview
      116. \r\n\r\nProducts Offered
      117. \r\n\r\nKey Developments
      118. \r\n\r\nSWOT Analysis
      119. \r\n\r\nKey Strategies
      120. \r\n\r\nElekta
      121. \r\n\r\nFinancial Overview
      122. \r\n\r\nProducts Offered
      123. \r\n\r\nKey Developments
      124. \r\n\r\nSWOT Analysis
      125. \r\n\r\nKey Strategies
      126. \r\n\r\nSiemens
      127. \r\n\r\nFinancial Overview
      128. \r\n\r\nProducts Offered
      129. \r\n\r\nKey Developments
      130. \r\n\r\nSWOT Analysis
      131. \r\n\r\nKey Strategies
      132. \r\n\r\nGeneral Electric
      133. \r\n\r\nFinancial Overview
      134. \r\n\r\nProducts Offered
      135. \r\n\r\nKey Developments
      136. \r\n\r\nSWOT Analysis
      137. \r\n\r\nKey Strategies
      138. \r\n\r\nAppendix
      139. \r\n\r\nReferences
      140. \r\n\r\nRelated Reports
      141. \r\n\r\n
      142. LIST Of tables
      143. \r\n
      144. \r\n
      145. \r\nLIST OF ASSUMPTIONS
    6. \r\n\r\nNorth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    7. \r\n\r\nNorth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    8. \r\n\r\nNorth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    9. \r\n\r\nNorth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    10. \r\n\r\nNorth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    11. \r\n\r\nUS Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    12. \r\n\r\nUS Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    13. \r\n\r\nUS Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    14. \r\n\r\nUS Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    15. \r\n\r\nUS Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    16. \r\n\r\nCanada Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    17. \r\n\r\nCanada Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    18. \r\n\r\nCanada Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    19. \r\n\r\nCanada Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    20. \r\n\r\nCanada Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    21. \r\n\r\nEurope Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    22. \r\n\r\nEurope Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    23. \r\n\r\nEurope Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    24. \r\n\r\nEurope Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    25. \r\n\r\nEurope Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    26. \r\n\r\nGermany Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    27. \r\n\r\nGermany Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    28. \r\n\r\nGermany Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    29. \r\n\r\nGermany Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    30. \r\n\r\nGermany Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    31. \r\n\r\nUK Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    32. \r\n\r\nUK Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    33. \r\n\r\nUK Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    34. \r\n\r\nUK Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    35. \r\n\r\nUK Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    36. \r\n\r\nFrance Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    37. \r\n\r\nFrance Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    38. \r\n\r\nFrance Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    39. \r\n\r\nFrance Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    40. \r\n\r\nFrance Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    41. \r\n\r\nRussia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    42. \r\n\r\nRussia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    43. \r\n\r\nRussia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    44. \r\n\r\nRussia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    45. \r\n\r\nRussia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    46. \r\n\r\nItaly Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    47. \r\n\r\nItaly Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    48. \r\n\r\nItaly Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    49. \r\n\r\nItaly Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    50. \r\n\r\nItaly Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    51. \r\n\r\nSpain Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    52. \r\n\r\nSpain Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    53. \r\n\r\nSpain Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    54. \r\n\r\nSpain Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    55. \r\n\r\nSpain Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    56. \r\n\r\nRest of Europe Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    57. \r\n\r\nRest of Europe Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    58. \r\n\r\nRest of Europe Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    59. \r\n\r\nRest of Europe Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    60. \r\n\r\nRest of Europe Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    61. \r\n\r\nAPAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    62. \r\n\r\nAPAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    63. \r\n\r\nAPAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    64. \r\n\r\nAPAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    65. \r\n\r\nAPAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    66. \r\n\r\nChina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    67. \r\n\r\nChina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    68. \r\n\r\nChina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    69. \r\n\r\nChina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    70. \r\n\r\nChina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    71. \r\n\r\nIndia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    72. \r\n\r\nIndia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    73. \r\n\r\nIndia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    74. \r\n\r\nIndia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    75. \r\n\r\nIndia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    76. \r\n\r\nJapan Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    77. \r\n\r\nJapan Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    78. \r\n\r\nJapan Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    79. \r\n\r\nJapan Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    80. \r\n\r\nJapan Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    81. \r\n\r\nSouth Korea Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    82. \r\n\r\nSouth Korea Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    83. \r\n\r\nSouth Korea Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    84. \r\n\r\nSouth Korea Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    85. \r\n\r\nSouth Korea Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    86. \r\n\r\nMalaysia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    87. \r\n\r\nMalaysia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    88. \r\n\r\nMalaysia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    89. \r\n\r\nMalaysia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    90. \r\n\r\nMalaysia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    91. \r\n\r\nThailand Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    92. \r\n\r\nThailand Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    93. \r\n\r\nThailand Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    94. \r\n\r\nThailand Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    95. \r\n\r\nThailand Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    96. \r\n\r\nIndonesia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    97. \r\n\r\nIndonesia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    98. \r\n\r\nIndonesia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    99. \r\n\r\nIndonesia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    100. \r\n\r\nIndonesia Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    101. \r\n\r\nRest of APAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    102. \r\n\r\nRest of APAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    103. \r\n\r\nRest of APAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    104. \r\n\r\nRest of APAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    105. \r\n\r\nRest of APAC Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    106. \r\n\r\nSouth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    107. \r\n\r\nSouth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    108. \r\n\r\nSouth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    109. \r\n\r\nSouth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    110. \r\n\r\nSouth America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    111. \r\n\r\nBrazil Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    112. \r\n\r\nBrazil Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    113. \r\n\r\nBrazil Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    114. \r\n\r\nBrazil Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    115. \r\n\r\nBrazil Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    116. \r\n\r\nMexico Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    117. \r\n\r\nMexico Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    118. \r\n\r\nMexico Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    119. \r\n\r\nMexico Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    120. \r\n\r\nMexico Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    121. \r\n\r\nArgentina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    122. \r\n\r\nArgentina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    123. \r\n\r\nArgentina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    124. \r\n\r\nArgentina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    125. \r\n\r\nArgentina Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    126. \r\n\r\nRest of South America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    127. \r\n\r\nRest of South America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    128. \r\n\r\nRest of South America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    129. \r\n\r\nRest of South America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    130. \r\n\r\nRest of South America Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    131. \r\n\r\nMEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    132. \r\n\r\nMEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    133. \r\n\r\nMEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    134. \r\n\r\nMEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    135. \r\n\r\nMEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    136. \r\n\r\nGCC Countries Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    137. \r\n\r\nGCC Countries Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    138. \r\n\r\nGCC Countries Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    139. \r\n\r\nGCC Countries Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    140. \r\n\r\nGCC Countries Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    141. \r\n\r\nSouth Africa Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    142. \r\n\r\nSouth Africa Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    143. \r\n\r\nSouth Africa Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    144. \r\n\r\nSouth Africa Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    145. \r\n\r\nSouth Africa Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
    146. \r\n\r\nRest of MEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    147. \r\n\r\nRest of MEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE TYPE, 2019-2035 (USD Billions)
    148. \r\n\r\nRest of MEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    149. \r\n\r\nRest of MEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY PROCEDURE, 2019-2035 (USD Billions)
    150. \r\n\r\nRest of MEA Nuclear Medicine Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD Billions)
      1. \r\n\r\nPRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
      2. \r\n\r\nACQUISITION/PARTNERSHIP
      3. \r\n\r\n
      4. \r\n
      5. \r\n
      6. \r\n
      7. \r\n
      8. \r\n
      9. \r\n
      10. \r\n
      11. \r\n
      12. \r\n
      13. \r\n
      14. \r\n
      15. \r\n
      16. \r\n
      17. \r\n
      18. \r\n
      19. \r\n
      20. \r\n
      21. \r\n
      22. \r\n
      23. \r\n
      24. \r\n
      25. \r\n
      26. \r\n
      27. \r\n
      28. \r\n
      29. \r\n
      30. \r\n
      31. \r\n
      32. \r\n
      33. LIST Of figures
      34. \r\n
      35. \r\n
      36. \r\nMARKET SYNOPSIS
      37. \r\n\r\nNORTH AMERICA NUCLEAR MEDICINE MARKET ANALYSIS
      38. \r\n\r\nUS NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      39. \r\n\r\nUS NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      40. \r\n\r\nUS NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      41. \r\n\r\nUS NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      42. \r\n\r\nUS NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      43. \r\n\r\nCANADA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      44. \r\n\r\nCANADA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      45. \r\n\r\nCANADA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      46. \r\n\r\nCANADA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      47. \r\n\r\nCANADA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      48. \r\n\r\nEUROPE NUCLEAR MEDICINE MARKET ANALYSIS
      49. \r\n\r\nGERMANY NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      50. \r\n\r\nGERMANY NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      51. \r\n\r\nGERMANY NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      52. \r\n\r\nGERMANY NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      53. \r\n\r\nGERMANY NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      54. \r\n\r\nUK NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      55. \r\n\r\nUK NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      56. \r\n\r\nUK NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      57. \r\n\r\nUK NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      58. \r\n\r\nUK NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      59. \r\n\r\nFRANCE NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      60. \r\n\r\nFRANCE NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      61. \r\n\r\nFRANCE NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      62. \r\n\r\nFRANCE NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      63. \r\n\r\nFRANCE NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      64. \r\n\r\nRUSSIA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      65. \r\n\r\nRUSSIA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      66. \r\n\r\nRUSSIA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      67. \r\n\r\nRUSSIA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      68. \r\n\r\nRUSSIA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      69. \r\n\r\nITALY NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      70. \r\n\r\nITALY NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      71. \r\n\r\nITALY NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      72. \r\n\r\nITALY NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      73. \r\n\r\nITALY NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      74. \r\n\r\nSPAIN NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      75. \r\n\r\nSPAIN NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      76. \r\n\r\nSPAIN NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      77. \r\n\r\nSPAIN NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      78. \r\n\r\nSPAIN NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      79. \r\n\r\nREST OF EUROPE NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      80. \r\n\r\nREST OF EUROPE NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      81. \r\n\r\nREST OF EUROPE NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      82. \r\n\r\nREST OF EUROPE NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      83. \r\n\r\nREST OF EUROPE NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      84. \r\n\r\nAPAC NUCLEAR MEDICINE MARKET ANALYSIS
      85. \r\n\r\nCHINA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      86. \r\n\r\nCHINA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      87. \r\n\r\nCHINA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      88. \r\n\r\nCHINA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      89. \r\n\r\nCHINA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      90. \r\n\r\nINDIA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      91. \r\n\r\nINDIA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      92. \r\n\r\nINDIA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      93. \r\n\r\nINDIA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      94. \r\n\r\nINDIA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      95. \r\n\r\nJAPAN NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      96. \r\n\r\nJAPAN NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      97. \r\n\r\nJAPAN NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      98. \r\n\r\nJAPAN NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      99. \r\n\r\nJAPAN NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      100. \r\n\r\nSOUTH KOREA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      101. \r\n\r\nSOUTH KOREA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      102. \r\n\r\nSOUTH KOREA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      103. \r\n\r\nSOUTH KOREA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      104. \r\n\r\nSOUTH KOREA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      105. \r\n\r\nMALAYSIA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      106. \r\n\r\nMALAYSIA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      107. \r\n\r\nMALAYSIA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      108. \r\n\r\nMALAYSIA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      109. \r\n\r\nMALAYSIA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      110. \r\n\r\nTHAILAND NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      111. \r\n\r\nTHAILAND NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      112. \r\n\r\nTHAILAND NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      113. \r\n\r\nTHAILAND NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      114. \r\n\r\nTHAILAND NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      115. \r\n\r\nINDONESIA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      116. \r\n\r\nINDONESIA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      117. \r\n\r\nINDONESIA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      118. \r\n\r\nINDONESIA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      119. \r\n\r\nINDONESIA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      120. \r\n\r\nREST OF APAC NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      121. \r\n\r\nREST OF APAC NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      122. \r\n\r\nREST OF APAC NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      123. \r\n\r\nREST OF APAC NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      124. \r\n\r\nREST OF APAC NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      125. \r\n\r\nSOUTH AMERICA NUCLEAR MEDICINE MARKET ANALYSIS
      126. \r\n\r\nBRAZIL NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      127. \r\n\r\nBRAZIL NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      128. \r\n\r\nBRAZIL NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      129. \r\n\r\nBRAZIL NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      130. \r\n\r\nBRAZIL NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      131. \r\n\r\nMEXICO NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      132. \r\n\r\nMEXICO NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      133. \r\n\r\nMEXICO NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      134. \r\n\r\nMEXICO NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      135. \r\n\r\nMEXICO NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      136. \r\n\r\nARGENTINA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      137. \r\n\r\nARGENTINA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      138. \r\n\r\nARGENTINA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      139. \r\n\r\nARGENTINA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      140. \r\n\r\nARGENTINA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      141. \r\n\r\nREST OF SOUTH AMERICA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      142. \r\n\r\nREST OF SOUTH AMERICA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      143. \r\n\r\nREST OF SOUTH AMERICA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      144. \r\n\r\nREST OF SOUTH AMERICA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      145. \r\n\r\nREST OF SOUTH AMERICA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      146. \r\n\r\nMEA NUCLEAR MEDICINE MARKET ANALYSIS
      147. \r\n\r\nGCC COUNTRIES NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      148. \r\n\r\nGCC COUNTRIES NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      149. \r\n\r\nGCC COUNTRIES NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      150. \r\n\r\nGCC COUNTRIES NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      151. \r\n\r\nGCC COUNTRIES NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      152. \r\n\r\nSOUTH AFRICA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      153. \r\n\r\nSOUTH AFRICA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      154. \r\n\r\nSOUTH AFRICA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      155. \r\n\r\nSOUTH AFRICA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      156. \r\n\r\nSOUTH AFRICA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      157. \r\n\r\nREST OF MEA NUCLEAR MEDICINE MARKET ANALYSIS BY APPLICATION
      158. \r\n\r\nREST OF MEA NUCLEAR MEDICINE MARKET ANALYSIS BY RADIOISOTOPE TYPE
      159. \r\n\r\nREST OF MEA NUCLEAR MEDICINE MARKET ANALYSIS BY END USER
      160. \r\n\r\nREST OF MEA NUCLEAR MEDICINE MARKET ANALYSIS BY PROCEDURE
      161. \r\n\r\nREST OF MEA NUCLEAR MEDICINE MARKET ANALYSIS BY REGIONAL
      162. \r\n\r\nKEY BUYING CRITERIA OF NUCLEAR MEDICINE MARKET
      163. \r\n\r\nRESEARCH PROCESS OF MRFR
      164. \r\n\r\nDRO ANALYSIS OF NUCLEAR MEDICINE MARKET
      165. \r\n\r\nDRIVERS IMPACT ANALYSIS: NUCLEAR MEDICINE MARKET
      166. \r\n\r\nRESTRAINTS IMPACT ANALYSIS: NUCLEAR MEDICINE MARKET
      167. \r\n\r\nSUPPLY / VALUE CHAIN: NUCLEAR MEDICINE MARKET
    151. \r\n\r\nNUCLEAR MEDICINE MARKET, BY APPLICATION, 2025 (% SHARE)
    152. \r\n\r\nNUCLEAR MEDICINE MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
    153. \r\n\r\nNUCLEAR MEDICINE MARKET, BY RADIOISOTOPE TYPE, 2025 (% SHARE)
    154. \r\n\r\nNUCLEAR MEDICINE MARKET, BY RADIOISOTOPE TYPE, 2019 TO 2035 (USD Billions)
    155. \r\n\r\nNUCLEAR MEDICINE MARKET, BY END USER, 2025 (% SHARE)
    156. \r\n\r\nNUCLEAR MEDICINE MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    157. \r\n\r\nNUCLEAR MEDICINE MARKET, BY PROCEDURE, 2025 (% SHARE)
    158. \r\n\r\nNUCLEAR MEDICINE MARKET, BY PROCEDURE, 2019 TO 2035 (USD Billions)
    159. \r\n\r\nNUCLEAR MEDICINE MARKET, BY REGIONAL, 2025 (% SHARE)
    160. \r\n\r\nNUCLEAR MEDICINE MARKET, BY REGIONAL, 2019 TO 2035 (USD Billions)
      1. \r\n\r\nBENCHMARKING OF MAJOR COMPETITORS
      2. \r\n\r\n

    Nuclear Medicine Market Segmentation

    Nuclear Medicine Market By Application (USD Billion, 2019-2035)

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    Nuclear Medicine Market By Radioisotope Type (USD Billion, 2019-2035)

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    Nuclear Medicine Market By End User (USD Billion, 2019-2035)

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    Nuclear Medicine Market By Procedure (USD Billion, 2019-2035)

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    Nuclear Medicine Market By Regional (USD Billion, 2019-2035)

    North America

    Europe

    South America

    Asia Pacific

    Middle East and Africa

    Nuclear Medicine Market Regional Outlook (USD Billion, 2019-2035)

    North America Outlook (USD Billion, 2019-2035)

    North America Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    North America Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    North America Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    North America Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    North America Nuclear Medicine Market by Regional Type

    US

    Canada

    US Outlook (USD Billion, 2019-2035)

    US Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    US Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    US Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    US Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    CANADA Outlook (USD Billion, 2019-2035)

    CANADA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    CANADA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    CANADA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    CANADA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    Europe Outlook (USD Billion, 2019-2035)

    Europe Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    Europe Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    Europe Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    Europe Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    Europe Nuclear Medicine Market by Regional Type

    Germany

    UK

    France

    Russia

    Italy

    Spain

    Rest of Europe

    GERMANY Outlook (USD Billion, 2019-2035)

    GERMANY Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    GERMANY Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    GERMANY Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    GERMANY Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    UK Outlook (USD Billion, 2019-2035)

    UK Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    UK Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    UK Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    UK Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    FRANCE Outlook (USD Billion, 2019-2035)

    FRANCE Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    FRANCE Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    FRANCE Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    FRANCE Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    RUSSIA Outlook (USD Billion, 2019-2035)

    RUSSIA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    RUSSIA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    RUSSIA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    RUSSIA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    ITALY Outlook (USD Billion, 2019-2035)

    ITALY Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    ITALY Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    ITALY Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    ITALY Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    SPAIN Outlook (USD Billion, 2019-2035)

    SPAIN Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    SPAIN Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    SPAIN Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    SPAIN Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    REST OF EUROPE Outlook (USD Billion, 2019-2035)

    REST OF EUROPE Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    REST OF EUROPE Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    REST OF EUROPE Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    REST OF EUROPE Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    APAC Outlook (USD Billion, 2019-2035)

    APAC Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    APAC Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    APAC Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    APAC Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    APAC Nuclear Medicine Market by Regional Type

    China

    India

    Japan

    South Korea

    Malaysia

    Thailand

    Indonesia

    Rest of APAC

    CHINA Outlook (USD Billion, 2019-2035)

    CHINA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    CHINA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    CHINA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    CHINA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    INDIA Outlook (USD Billion, 2019-2035)

    INDIA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    INDIA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    INDIA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    INDIA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    JAPAN Outlook (USD Billion, 2019-2035)

    JAPAN Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    JAPAN Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    JAPAN Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    JAPAN Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    SOUTH KOREA Outlook (USD Billion, 2019-2035)

    SOUTH KOREA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    SOUTH KOREA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    SOUTH KOREA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    SOUTH KOREA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    MALAYSIA Outlook (USD Billion, 2019-2035)

    MALAYSIA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    MALAYSIA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    MALAYSIA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    MALAYSIA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    THAILAND Outlook (USD Billion, 2019-2035)

    THAILAND Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    THAILAND Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    THAILAND Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    THAILAND Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    INDONESIA Outlook (USD Billion, 2019-2035)

    INDONESIA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    INDONESIA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    INDONESIA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    INDONESIA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    REST OF APAC Outlook (USD Billion, 2019-2035)

    REST OF APAC Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    REST OF APAC Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    REST OF APAC Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    REST OF APAC Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    South America Outlook (USD Billion, 2019-2035)

    South America Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    South America Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    South America Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    South America Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    South America Nuclear Medicine Market by Regional Type

    Brazil

    Mexico

    Argentina

    Rest of South America

    BRAZIL Outlook (USD Billion, 2019-2035)

    BRAZIL Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    BRAZIL Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    BRAZIL Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    BRAZIL Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    MEXICO Outlook (USD Billion, 2019-2035)

    MEXICO Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    MEXICO Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    MEXICO Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    MEXICO Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    ARGENTINA Outlook (USD Billion, 2019-2035)

    ARGENTINA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    ARGENTINA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    ARGENTINA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    ARGENTINA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)

    REST OF SOUTH AMERICA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    REST OF SOUTH AMERICA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    REST OF SOUTH AMERICA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    REST OF SOUTH AMERICA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    MEA Outlook (USD Billion, 2019-2035)

    MEA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    MEA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    MEA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    MEA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    MEA Nuclear Medicine Market by Regional Type

    GCC Countries

    South Africa

    Rest of MEA

    GCC COUNTRIES Outlook (USD Billion, 2019-2035)

    GCC COUNTRIES Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    GCC COUNTRIES Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    GCC COUNTRIES Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    GCC COUNTRIES Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    SOUTH AFRICA Outlook (USD Billion, 2019-2035)

    SOUTH AFRICA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    SOUTH AFRICA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    SOUTH AFRICA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    SOUTH AFRICA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

    REST OF MEA Outlook (USD Billion, 2019-2035)

    REST OF MEA Nuclear Medicine Market by Application Type

    Diagnostic Imaging

    Therapeutic Applications

    Radiopharmaceutical Production

    Research Applications

    REST OF MEA Nuclear Medicine Market by Radioisotope Type

    Technetium-99m

    Iodine-131

    Fluorine-18

    Yttrium-90

    REST OF MEA Nuclear Medicine Market by End User Type

    Hospitals

    Diagnostic Imaging Centers

    Academic Research Institutions

    Pharmaceutical Companies

    REST OF MEA Nuclear Medicine Market by Procedure Type

    Positron Emission Tomography

    Single-Photon Emission Computed Tomography

    Radiotherapy

    Brachytherapy

     

     

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027